Small molecules under development for psoriasis: on the road to the individualized therapies
Authors:
- Cervantes-Durán ClaudiaCCCervantes-Durán Claudia
- Velázquez-Hernández María-ElenaVMVelázquez-Hernández María-Elena
- Valentín-Escalera JosuéVJValentín-Escalera Josué
- Bartolomé-Camacho María-CarmenBMBartolomé-Camacho María-Carmen
- Rodríguez-Orozco Alain-RaimundoRARodríguez-Orozco Alain-Raimundo
- García-Pérez Martha-EstrellaGMGarcía-Pérez Martha-Estrella
- 14 March 2020
- journal article
- review article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 312 (9) , 611-627
Abstract
Psoriasis is an incurable cutaneous illness characterized by the presence of well-delimited reddish plaques and silvery-white dry scales. So far, there is a limited understanding of its pathogenesis, though recent discoveries on the immunological, genetic and molecular aspects of this disease have significantly contributed to the identification of new targets and the development of novel drugs. Despite these advances, many patients are still dissatisfied, so to improve patient satisfaction, reliability, and clinical outcomes, the individualization of the treatments for this disease becomes a necessity. This review summarizes recent findings related to psoriasis pathogenesis and describes new small molecules and targets recently identified as promising for treatments. Additionally, the current status, challenges and the future directions for achieving individualized therapy for this disease and the need for more collaborative studies are discussed. The individualization of treatments for psoriasis, rather than a goal, is analyzed as a process where a dynamic integration between the needs and characteristics of the patients, the pharmacological progress, and the clinical decisions takes place.Keywords
This publication has 102 references indexed in Scilit:
- Phosphodiesterase 4-targeted treatments for autoimmune diseasesBMC Medicine, 2013
- Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunityNature Genetics, 2012
- Keratinocytes under Fire of Proinflammatory Cytokines: Bona Fide Innate Immune Cells Involved in the Physiopathology of Chronic Atopic Dermatitis and PsoriasisJournal of Allergy, 2012
- Psoriasiform dermatitis is driven by IL-36–mediated DC-keratinocyte crosstalkJournal of Clinical Investigation, 2012
- Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8Journal of Experimental Medicine, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Adaptive Treatment Strategies in Chronic DiseaseAnnual Review of Medicine, 2008
- The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic inventionMolecular Cancer, 2007
- Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cellsBlood, 2006
- A mutation in Orai1 causes immune deficiency by abrogating CRAC channel functionNature, 2006